Add-On Cyclic Angiotensin-(1-7) with Cyclophosphamide Arrests Progressive Kidney Disease in Rats with ANCA Associated Glomerulonephritis
暂无分享,去创建一个
G. Remuzzi | A. Benigni | M. Abbate | C. Zoja | D. Rottoli | D. Corna | Domenico Cerullo | Daniela Rottoli
[1] L. Truong,et al. Angiotensin-converting enzyme 2 decreased expression during kidney inflammatory diseases: implications to predisposing to COVID-19 kidney complications , 2021, Kidney International.
[2] H. Trimarchi. Crescents in primary glomerulonephritis: a pattern of injury with dissimilar actors. A pathophysiologic perspective , 2021, Pediatric Nephrology.
[3] G. Remuzzi,et al. Characterization of a Rat Model of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Crescentic Glomerulonephritis , 2021, Nephron.
[4] H. Kono,et al. Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody(ANCA)-associated vasculitis , 2021, Journal of translational autoimmunity.
[5] H. Choi,et al. Angiotensin-[1–7] attenuates kidney injury in experimental Alport syndrome , 2020, Scientific Reports.
[6] H. Anders,et al. The glomerular crescent: triggers, evolution, resolution, and implications for therapy , 2020, Current opinion in nephrology and hypertension.
[7] P. Merkel,et al. ANCA-associated vasculitis , 2020, Nature Reviews Disease Primers.
[8] G. Remuzzi,et al. Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. , 2019, Kidney international.
[9] M. Teixeira,et al. Angiotensin-(1-7) and Alamandine Promote Anti-inflammatory Response in Macrophages In Vitro and In Vivo , 2019, Mediators of inflammation.
[10] G. Moll,et al. Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models , 2019, Peptides.
[11] J. Niles,et al. Renal Involvement in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. , 2018, Rheumatic diseases clinics of North America.
[12] D. Nikolic-Paterson,et al. An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis , 2018, International journal of immunopathology and pharmacology.
[13] D. Nikolic-Paterson,et al. Matrix metalloproteinase‐12 deficiency attenuates experimental crescentic anti‐glomerular basement membrane glomerulonephritis , 2016, Nephrology.
[14] M. Teixeira,et al. Angiotensin-(1-7) Promotes Resolution of Neutrophilic Inflammation in a Model of Antigen-Induced Arthritis in Mice , 2017, Front. Immunol..
[15] G. Remuzzi,et al. The Role of Angiotensin II in Parietal Epithelial Cell Proliferation and Crescent Formation in Glomerular Diseases. , 2017, The American journal of pathology.
[16] J. C. Jennette,et al. ANCA Glomerulonephritis and Vasculitis. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[17] J. Winkler,et al. Role of the receptor Mas in macrophage-mediated inflammation in vivo , 2016, Proceedings of the National Academy of Sciences.
[18] G. Remuzzi,et al. Inhibiting angiotensin-converting enzyme promotes renal repair by modulating progenitor cell activation. , 2016, Pharmacological research.
[19] G. Remuzzi,et al. Regression of Renal Disease by Angiotensin II Antagonism Is Caused by Regeneration of Kidney Vasculature. , 2016, Journal of the American Society of Nephrology.
[20] Lei Zhao,et al. M2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN. , 2015, Clinical journal of the American Society of Nephrology : CJASN.
[21] S. Nishio,et al. Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. , 2014, Journal of the American Society of Nephrology : JASN.
[22] J. Scholey,et al. Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. , 2014, American journal of physiology. Renal physiology.
[23] N. Perico,et al. Nature and mediators of parietal epithelial cell activation in glomerulonephritides of human and rat. , 2013, The American journal of pathology.
[24] M. Teixeira,et al. ACE2, angiotensin‐(1‐7) and Mas receptor axis in inflammation and fibrosis , 2013, British journal of pharmacology.
[25] C. Manthey,et al. Role of macrophages in the fibrotic phase of rat crescentic glomerulonephritis. , 2013, American journal of physiology. Renal physiology.
[26] L. P. de Sousa,et al. Anti-Inflammatory Effects of the Activation of the Angiotensin-(1–7) Receptor, Mas, in Experimental Models of Arthritis , 2010, The Journal of Immunology.
[27] W. Border,et al. Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. , 2010, American journal of physiology. Renal physiology.
[28] T. Walther,et al. Angiotensin-(1-7) with Thioether Bridge: An Angiotensin-Converting Enzyme-Resistant, Potent Angiotensin-(1-7) Analog , 2009, Journal of Pharmacology and Experimental Therapeutics.
[29] Y. Sado,et al. Podocytes contribute to the formation of glomerular crescents. , 2008, Journal of the American Society of Nephrology : JASN.
[30] M. Hickey,et al. Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis. , 2006, Journal of the American Society of Nephrology : JASN.
[31] N. Perico,et al. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. , 2005, Kidney international. Supplement.
[32] David Andreu,et al. The effect of cyclization on the enzymatic degradation of herpes simplex virus glycoprotein D derived epitope peptide , 2005, Journal of peptide science : an official publication of the European Peptide Society.
[33] P. Heeringa,et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. , 2005, The American journal of pathology.
[34] J. Jennette. Rapidly progressive crescentic glomerulonephritis. , 2003, Kidney international.
[35] C. Svensson,et al. Synthesis and biological activities of cyclic lanthionine enkephalin analogues : δ-opioid receptor selective ligands , 2002 .
[36] P. Patston,et al. Release and degradation of angiotensin I and angiotensin II from angiotensinogen by neutrophil serine proteinases. , 2002, Archives of biochemistry and biophysics.
[37] D. Ganten,et al. Converting enzyme determines plasma clearance of angiotensin-(1-7). , 1998, Hypertension.
[38] J. Nishiyama,et al. Acute glomerulonephritis. , 2000, Internal medicine.
[39] M. Wigler,et al. Characterization of the rat mas oncogene and its high-level expression in the hippocampus and cerebral cortex of rat brain. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[40] V. Dzau,et al. Human neutrophils release serine proteases capable of activating prorenin. , 1987, Circulation research.